Not all biotech money is the same money. A founder raising a first round needs to understand that venture firms come in distinct flavors, and pitching a company-creation fund the same way you would pitch a crossover investor is a fast way to waste everyone’s time. This is a map of the early-stage biotech landscape, organized by how firms actually work, with the names worth knowing in each category.
One note before the names: this is a guide to how these firms invest, not a ranking, and it is not investment or fundraising advice. Fund strategies shift, so treat it as a starting point for your own diligence.
The company creators
Some firms do not wait for founders to show up. They build companies in-house, forming a startup around a scientific thesis, incubating it, and staffing it, sometimes before there is a CEO at all. If your science fits their thesis, these are extraordinary partners; if you are a founder looking for a check to run your own company your way, the fit can be trickier.
The archetype is Flagship Pioneering, which originated Moderna and runs an explicit venture-creation engine. Third Rock Ventures similarly builds companies around ambitious science with heavy hands-on involvement in the early years. For deep-science founders whose work matches the model, these firms bring far more than money.
The early-stage specialists
These are the classic biotech venture firms: they lead seed and Series A rounds, take board seats, and shepherd companies through the long preclinical and early-clinical slog. They are where most first institutional checks come from.
Names that consistently anchor early rounds include ARCH Venture Partners, known for backing bold, science-first companies early; Atlas Venture, a fixture in the Boston ecosystem with a seed-led model; Versant Ventures; 5AM Ventures; Polaris Partners; The Column Group, which leans toward deep biology; and venBio. In Europe, Sofinnova Partners and Forbion play a similar anchoring role. These are the firms whose partners you want in your corner for the first five years.
The multi-stage and generalist-with-a-biotech-arm firms
Some large firms invest across the life of a company, from early rounds through crossover and beyond, and others are tech-native generalists that have built serious life-science practices. OrbiMed and RA Capital Management are the classic multi-stage healthcare investors, active from private rounds into the public markets. Andreessen Horowitz (through its Bio and Health practice) and GV bring a technology investor’s lens, which matters more every year as computation reshapes drug discovery. Foresite Capital and Deerfield round out the group of firms comfortable writing checks at multiple stages.
The crossover investors
Crossover funds invest in the last private round before an IPO and then continue buying in the public offering. They are not who you pitch at seed, but they matter enormously as you approach the public markets, because their participation signals quality to other public investors. Many of the multi-stage firms above play this role, alongside dedicated public-market healthcare specialists. The practical lesson for early founders: build relationships with these funds a round or two before you need them, not the week you file to go public.
How to figure out which firm fits you
The single most common fundraising mistake is pitching the wrong type of investor. A few questions sharpen the target:
- What stage do they actually lead? A firm that writes $50 million Series B checks is not going to lead your $4 million seed, no matter how much they like the science.
- What is their thesis? Many firms are quietly specialized, in a modality, a therapeutic area, or a scientific approach. Pitching a platform they have publicly cooled on is wasted effort.
- How hands-on are they? Company creators and early specialists take active board roles; some multi-stage funds are more passive. Decide how much involvement you want.
- Who have they backed that looks like you? Their portfolio is the clearest statement of what they will fund next.
Do the homework before you send the email
The founders who raise efficiently are the ones who research first and pitch second. Rather than blasting a deck to fifty firms, they identify the ten whose stage, thesis, and portfolio genuinely fit, and they get a warm introduction to each. That targeting is the difference between a two-month raise and a nine-month one.
Do not forget corporate venture and strategic money
Beyond the classic financial VCs, most large pharma companies run their own venture arms, and they are a distinct and valuable source of capital. Groups attached to the major pharmas invest in emerging companies both for financial return and for a window into science that might matter to the parent. Strategic money like this can bring more than a check, real drug-development expertise, credibility, and sometimes a future partner, but it can also come with considerations around information rights and future deal dynamics that pure financial investors do not carry. For many founders the right answer is a syndicate that blends financial and strategic investors, capturing the expertise without ceding too much strategic optionality.
The money that does not dilute you
Venture capital is not the only game. Non-dilutive funding, money you do not give up equity for, can extend runway and de-risk a program before you raise. Government grants, disease-foundation funding, and public programs aimed at specific areas like infectious disease or rare disease can be meaningful, especially early. It is often slower and more restricted than venture money, and it rarely replaces a real round, but a well-timed grant can fund a key experiment, strengthen your data package, and let you raise your next round from a position of strength. The savviest early founders treat dilutive and non-dilutive sources as complementary, not either-or.
How to actually get the meeting
Knowing which firm fits is only half the job; you still have to get in the door, and in venture, the warm introduction remains the strongest currency. A cold email to a partner has a low hit rate; the same pitch arriving through a founder they have backed, an advisor they respect, or a co-investor they trust gets read and taken seriously. So before you send anything, map your path to each target firm: who in your network knows someone there? Founders in a firm’s portfolio are often the best route, since a positive word from a company they funded carries real weight. If you have no warm path at all, a genuinely specific, concise note that shows you understand exactly why this firm fits, referencing a relevant portfolio company or thesis, beats a generic mass email. Fundraising is a relationship business well before it is a numbers business, and the founders who internalize that raise faster.
Geography shapes investor style
Where an investor sits shapes how it behaves. US firms, concentrated in Boston and the Bay Area, tend to move fast and write large rounds. European investors are often more syndicate-oriented and can bring valuable non-dilutive and strategic connections. Asian capital has grown enormously and can open doors to specific markets and partners. None of this is a rule, only a tendency, but if you are building a cap table with an eye to where you will eventually raise, partner, or sell, the geography of your early investors is worth thinking about rather than treating all money as interchangeable.
To build that target list, the BioMed Nexus biotech venture capital directory organizes investors by type, from early-stage and company-creation funds to crossover and corporate venture arms, so you can filter to the firms that actually match your round. And because knowing who just raised a new fund or made a fresh bet is half of good targeting, the daily brief tracks venture activity across the industry as it happens.
Frequently asked questions
Which VC firms invest in early-stage biotech?
Early-stage biotech rounds are frequently led by specialists such as ARCH Venture Partners, Atlas Venture, Versant Ventures, 5AM Ventures, Polaris Partners, The Column Group and venBio, alongside company-creation firms like Flagship Pioneering and Third Rock Ventures, and European anchors such as Sofinnova Partners and Forbion.
What is a company-creation VC firm?
A company-creation firm builds startups in-house rather than waiting for founders to pitch. It forms a company around a scientific thesis, incubates it, and staffs it, often before a CEO is in place. Flagship Pioneering and Third Rock Ventures are the best-known examples in biotech.
What is a crossover investor in biotech?
A crossover investor participates in a company's final private round and then continues buying shares in its public offering. Their involvement signals quality to other public-market investors, so founders benefit from building relationships with them a round or two before an IPO.
